o NoneEntity Type
0001372299
HISTOGENICS CORP
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 Ocugen, Inc.
Jurisdiction of Incorporation/OrganizationDELAWARE 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Ocugen, Inc. 
Street Address 1Street Address 2
 5 GREAT VALLEY PARKWAY SUITE 160
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 MALVERN PENNSYLVANIA 19355 484-328-4698 



3. Related Persons
Last NameFirst NameMiddle Name
MusunuriShankar
Street Address 1Street Address 2
5 Great Valley Parkway, Suite 160
CityState/Province/CountryZIP/Postal Code
MalvernPENNSYLVANIA19355
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 Chief Executive Officer and Chairman

Last NameFirst NameMiddle Name
KumarRamesh
Street Address 1Street Address 2
5 Great Valley Parkway, Suite 160
CityState/Province/CountryZIP/Postal Code
MalvernPENNSYLVANIA19355
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
ZhangJunge
Street Address 1Street Address 2
5 Great Valley Parkway, Suite 160
CityState/Province/CountryZIP/Postal Code
MalvernPENNSYLVANIA19355
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
KompellaUdayB
Street Address 1Street Address 2
5 Great Valley Parkway, Suite 160
CityState/Province/CountryZIP/Postal Code
MalvernPENNSYLVANIA19355
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
PottiManish
Street Address 1Street Address 2
5 Great Valley Parkway, Suite 160
CityState/Province/CountryZIP/Postal Code
MalvernPENNSYLVANIA19355
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
CastilloKristen
Street Address 1Street Address 2
5 Great Valley Parkway, Suite 160
CityState/Province/CountryZIP/Postal Code
MalvernPENNSYLVANIA19355
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
FernandesPrabhavathi
Street Address 1Street Address 2
5 Great Valley Parkway, Suite 160
CityState/Province/CountryZIP/Postal Code
MalvernPENNSYLVANIA19355
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
TaspolatogluSuha
Street Address 1Street Address 2
5 Great Valley Parkway, Suite 160
CityState/Province/CountryZIP/Postal Code
MalvernPENNSYLVANIA19355
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
SubramanianSanjay
Street Address 1Street Address 2
5 Great Valley Parkway, Suite 160
CityState/Province/CountryZIP/Postal Code
MalvernPENNSYLVANIA19355
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
JorgensenDaniel
Street Address 1Street Address 2
5 Great Valley Parkway, Suite 160
CityState/Province/CountryZIP/Postal Code
MalvernPENNSYLVANIA19355
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
ArumughamRasappa
Street Address 1Street Address 2
5 Great Valley Parkway, Suite 160
CityState/Province/CountryZIP/Postal Code
MalvernPENNSYLVANIA19355
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
BeckKelly
Street Address 1Street Address 2
5 Great Valley Parkway, Suite 160
CityState/Province/CountryZIP/Postal Code
MalvernPENNSYLVANIA19355
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
TammaraVijay
Street Address 1Street Address 2
5 Great Valley Parkway, Suite 160
CityState/Province/CountryZIP/Postal Code
MalvernPENNSYLVANIA19355
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   x Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  o Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2020-04-22 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests x Equity
o Tenant-in-Common Securities x Debt
o Mineral Property Securities o Option, Warrant or Other Right to Acquire Another Security
o Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
  
(Associated) Broker or Dealer o None(Associated) Broker or Dealer CRD Number o None
  
Street Address 1Street Address 2
  
City State/Province/CountryZIP/Postal Code
   
State(s) of Solicitation o All States
 
 



13. Offering and Sales Amounts
Total Offering Amount $ 14283724 USD o Indefinite
Total Amount Sold $ 14283724 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
 21,920,820 shares of common stock and $5.625 million in aggregate principal amount of promissory notes issued in exchange for outstanding Series A Warrants.


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 6


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 0 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ocugen Charts.
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ocugen Charts.

Ocugen, Inc. News

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
Friday 3 May 2024 (3 days ago) • GlobeNewswire Inc.
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
Thursday 2 May 2024 (4 days ago) • GlobeNewswire Inc.
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
Monday 29 April 2024 (1 week ago) • GlobeNewswire Inc.
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Friday 26 April 2024 (1 week ago) • GlobeNewswire Inc.
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Friday 26 April 2024 (1 week ago) • GlobeNewswire Inc.
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
Friday 19 April 2024 (2 weeks ago) • GlobeNewswire Inc.
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
Friday 12 April 2024 (3 weeks ago) • GlobeNewswire Inc.
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Wednesday 10 April 2024 (4 weeks ago) • GlobeNewswire Inc.
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
Monday 8 April 2024 (4 weeks ago) • GlobeNewswire Inc.
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
Friday 5 April 2024 (1 month ago) • GlobeNewswire Inc.
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
Tuesday 2 April 2024 (1 month ago) • GlobeNewswire Inc.
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
Monday 1 April 2024 (1 month ago) • GlobeNewswire Inc.

More Ocugen, Inc. News Articles